The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will meet on Wednesday, November 13, to review and discuss the marketing application from Boehringer Ingelheim seeking approval to use Jardiance (empagliflozin) to treat adults with type 1 diabetes.
Jardiance is currently approved in the U.S. for type 2 diabetes.
Related ticker: Eli Lilly (LLY +0.6%)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.